

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KKR Genetic Disorder L.P.</u> <hr/> (Last) (First) (Middle) <u>9 WEST 57TH STREET, SUITE 4200</u> <hr/> (Street) <u>NEW YORK NY 10019</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BridgeBio Pharma, Inc. [BBIO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/28/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/28/2020		s		2,389,690	D	\$33.39	34,510,971	I	See footnotes ⁽¹⁾⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
KKR Genetic Disorder L.P.

 (Last) (First) (Middle)
9 WEST 57TH STREET, SUITE 4200

 (Street)
NEW YORK NY 10019

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
KKR Genetic Disorder GP LLC

 (Last) (First) (Middle)
9 WEST 57TH STREET, SUITE 4200

 (Street)
NEW YORK, NY 10019

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
KKR Group Partnership L.P.

 (Last) (First) (Middle)
9 WEST 57TH STREET, SUITE 4200

 (Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Group Holdings Corp.](#)

(Last) (First) (Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR & Co. Inc.](#)

(Last) (First) (Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KKR Management LLP](#)

(Last) (First) (Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[KRAVIS HENRY R](#)

(Last) (First) (Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ROBERTS GEORGE R](#)

(Last) (First) (Middle)

2800 SAND HILL ROAD, SUITE 200

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

Explanation of Responses:

1. The securities of the Issuer are held by KKR Genetic Disorder L.P, KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

2. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

Remarks:

Exhibit 24 - Power of Attorney

[KKR GENETIC DISORDER](#) [06/01/2020](#)

[L.P By: KKR Genetic](#)

[Disorder GP LLC, its general](#)

<u>partner By: /s/ Terence P.</u>	
<u>Gallagher Name: Terence P.</u>	
<u>Gallagher Title: Attorney-in-</u>	
<u>fact for Robert H. Lewin,</u>	
<u>Chief Financial Officer</u>	
<u>KKR GENETIC DISORDER</u>	
<u>GP LLC By: /s/ Terence P.</u>	
<u>Gallagher Name: Terence P.</u>	<u>06/01/2020</u>
<u>Gallagher Title: Attorney-in-</u>	
<u>fact for Robert H. Lewin,</u>	
<u>Chief Financial Officer</u>	
<u>KKR GROUP</u>	
<u>PARTNERSHIP L.P. By:</u>	
<u>KKR Group Holdings Corp.,</u>	
<u>its general partner By: /s/</u>	
<u>Terence P. Gallagher Name:</u>	<u>06/01/2020</u>
<u>Terence P. Gallagher Title:</u>	
<u>Attorney-in-fact for Robert H.</u>	
<u>Lewin, Chief Financial Officer</u>	
<u>KKR GROUP HOLDINGS</u>	
<u>CORP. By: /s/ Terence P.</u>	
<u>Gallagher Name: Terence P.</u>	<u>06/01/2020</u>
<u>Gallagher Title: Attorney-in-</u>	
<u>fact for Robert H. Lewin,</u>	
<u>Chief Financial Officer</u>	
<u>KKR & CO. INC. By: /s/</u>	
<u>Terence P. Gallagher Name:</u>	
<u>Terence P. Gallagher Title:</u>	<u>06/01/2020</u>
<u>Attorney-in-fact for Robert H.</u>	
<u>Lewin, Chief Financial Officer</u>	
<u>KKR MANAGEMENT LLP</u>	
<u>By: /s/ Terence P. Gallagher</u>	
<u>Name: Terence P. Gallagher</u>	<u>06/01/2020</u>
<u>Title: Attorney-in-fact for</u>	
<u>Robert H. Lewin, Chief</u>	
<u>Financial Officer</u>	
<u>HENRY R. KRAVIS By: /s/</u>	
<u>Terence P. Gallagher Name:</u>	<u>06/01/2020</u>
<u>Terence P. Gallagher Title:</u>	
<u>Attorney-in-fact</u>	
<u>GEORGE R. ROBERTS By:</u>	
<u>/s/ Terence P. Gallagher</u>	<u>06/01/2020</u>
<u>Name: Terence P. Gallagher</u>	
<u>Title: Attorney-in-fact</u>	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all men by these presents that Robert H. Lewin does hereby make, constitute and appoint David J. Sorkin, Terence P. Gallagher, and Christopher Lee, or any one of them, as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead of the undersigned (both in the undersigned's individual capacity and as a manager or member of any limited liability company, as a partner of any partnership, as an officer of any corporate or other entity, or in the undersigned's capacity in a position similar to the foregoing at any entity, in each case, for which the undersigned is otherwise authorized to sign), to execute and deliver such forms, schedules, statements and other documents as may be required to be filed from time to time with the Securities and Exchange Commission with respect to: (i) Sections 13(d), 13(g), 13(f), 13(h) and 16(a) of the Securities Exchange Act of 1934, as amended, including without limitation, Schedule 13D, Schedule 13G, Form 13F, Form 13H, Form 3, Form 4 and Form 5 and (ii) in connection with any applications for EDGAR access codes, including without limitation the Form ID.

/s/ Robert H. Lewin

Name: Robert H. Lewin

Date: January 14, 2020
